Christian O. Henry Sells 10,500 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Christian O. Henry sold 10,500 shares of the business’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the sale, the director now owns 16,115 shares in the company, valued at approximately $157,443.55. The trade was a 39.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Wave Life Sciences Stock Performance

WVE stock traded down $0.08 during mid-day trading on Friday, reaching $9.59. 1,619,845 shares of the stock traded hands, compared to its average volume of 1,088,778. Wave Life Sciences Ltd. has a one year low of $4.25 and a one year high of $16.74. The stock has a market capitalization of $1.47 billion, a PE ratio of -8.64 and a beta of -1.04. The business has a 50-day moving average price of $10.95 and a two-hundred day moving average price of $11.48.

Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.34. The company had revenue of $83.75 million for the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. On average, equities analysts expect that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Wave Life Sciences

Hedge funds and other institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new position in Wave Life Sciences during the 4th quarter valued at $40,000. Quarry LP purchased a new stake in shares of Wave Life Sciences during the fourth quarter valued at $62,000. KBC Group NV purchased a new stake in shares of Wave Life Sciences during the fourth quarter valued at $67,000. Summit Investment Advisors Inc. grew its holdings in shares of Wave Life Sciences by 31.5% in the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock worth $119,000 after purchasing an additional 2,308 shares during the last quarter. Finally, Westwood Wealth Management purchased a new position in Wave Life Sciences in the 4th quarter worth about $124,000. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on WVE shares. StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Jefferies Financial Group initiated coverage on Wave Life Sciences in a report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a research report on Wednesday, March 5th. Finally, Mizuho increased their price objective on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $22.60.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.